Michigan Medicine: FDA-approved Drug Offers Hope for Patients With Polycythemia Vera, a Rare Bone Marrow Disorder
September 26, 2026
September 26, 2026
ANN ARBOR, Michigan, Sept. 26 -- Michigan Medicine, the academic medical center of the University of Michigan, issued the following news release:
* * *
Expert explains the symptoms, genetic causes and treatment benefits of the first-in-class drug rusfertide
September 24, 2026
Polycythemia vera is a rare bone marrow disorder affecting 90,000 people in the U.S. and is characterized by the overproduction of red blood cells.
Excessive . . .
* * *
Expert explains the symptoms, genetic causes and treatment benefits of the first-in-class drug rusfertide
September 24, 2026
Polycythemia vera is a rare bone marrow disorder affecting 90,000 people in the U.S. and is characterized by the overproduction of red blood cells.
Excessive . . .